RecruitingNCT06278532

Validation of the Lithuanian Version of the BNSS, CDSS, and the SCoRS

Validation of the Lithuanian Version of the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and the Schizophrenia Cognition Rating Scale

Sponsor

Lithuanian University of Health Sciences

Enrollment

200 participants

Start Date

Dec 11, 2023

Study Type

OBSERVATIONAL

Conditions

Schizophrenia Cognitive Deficit Negative Symptoms in Schizophrenia Depressive Symptoms Due to Primary Psychotic Disorder (Diagnosis)

Summary

This study aims to validate the Lithuanian version of the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and Schizophrenia Cognition Rating Scale in a Lithuanian sample. This will be done by comparing results obtained from the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and Schizophrenia Cognition Rating Scale with results obtained from the Positive and Negative Symptoms Scale, the Montgomery Asberg Depression Rating Scale, and the Montreal Cognitive Assessment test.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is validating Lithuanian-language versions of three rating scales used to assess symptoms in people with schizophrenia — specifically negative symptoms (like emotional flatness and withdrawal), depression, and cognitive problems. Validated tools improve the quality of psychiatric care. **You may be eligible if...** - You are between 18 and 65 years old - You have a diagnosis of schizophrenia, schizoaffective disorder, or schizotypal disorder - You have signed an informed consent form **You may NOT be eligible if...** - You are outside the 18-65 age range - You did not sign informed consent - You have a diagnosis of intellectual disability - You have substance or alcohol use disorder as a primary or co-occurring diagnosis - You have an organic brain disorder (e.g., dementia caused by brain injury or disease) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTBrief Negative Symptoms Scale

The Lithuanian Brief Negative Symptoms scale (BNSS) version will be used and validated. BNSS is used as a modern tool for the evaluation of negative symptoms of schizophrenia. Older tools used for negative symptoms evaluation often include symptoms from other dimensions of symptoms of schizophrenia, and BNSS evaluates negative symptoms specifically. BNSS is a semi-structured interview made of 13 items. There are six subscales: anhedonia (3 items), lack of normal distress (1 item), asociality (2 items), avolition (2 items), blunted affect (3 items) and alogia (2 items).

DIAGNOSTIC_TESTThe Calgary Depression Scale for Schizophrenia

The Lithuanian version of the CDSS will be used and validated. CDSS is a tool used to evaluate depressive symptoms, specifically for patients with schizophrenia. Often, distinguishing between depressive and negative symptoms of schizophrenia is difficult. Therefore, it is recommended to use tools designed specifically for patients with schizophrenia. CDSS is the only depression scale designed to assess depression in people with a schizophrenia syndrome disorder. It is a semi-structured interview consisting of 9 items.

DIAGNOSTIC_TESTThe Schizophrenia Cognition Rating Scale

The Lithuanian version of the SCoRS will be used and validated. SCoRS is a 20-item interview-based assessment tool that evaluates cognitive deficits and the degree to which these deficits impair specifically in patients with schizophrenia.